by | May 12, 2024 | Publications
Cancers (Basel). 2024 May 4;16(9):1774. doi: 10.3390/cancers16091774. ABSTRACT Because of the high prevalence of bone destruction in patients with multiple myeloma (MM), physical exercise is oftentimes discouraged by healthcare providers. The goal of this prospective...
by | May 12, 2024 | Publications
J Clin Med. 2024 May 2;13(9):2679. doi: 10.3390/jcm13092679. ABSTRACT Objectives: To verify medication-related osteonecrosis of the jaw (MRONJ) frequency among patients with plasma cell myeloma (PCM) that had been treated with bisphosphonates, to identify predisposing...
by | May 12, 2024 | Publications
Int J Mol Sci. 2024 Apr 26;25(9):4718. doi: 10.3390/ijms25094718. ABSTRACT Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion...
by | May 12, 2024 | Publications
Int J Mol Sci. 2024 Apr 30;25(9):4887. doi: 10.3390/ijms25094887. ABSTRACT Multiple myeloma is an incurable plasma cell malignancy. Most patients end up relapsing and developing resistance to antineoplastic drugs, like bortezomib. Antibiotic tigecycline has activity...
by | May 12, 2024 | Publications
Int J Mol Sci. 2024 May 3;25(9):4996. doi: 10.3390/ijms25094996. ABSTRACT Multiple myeloma (MM), the second most common hematologic malignancy, remains incurable, and its incidence is rising. Chimeric Antigen Receptor T-cell (CAR-T cell) therapy has emerged as a novel...
by | May 10, 2024 | Publications
Blood. 2024 May 10:blood.2023023557. doi: 10.1182/blood.2023023557. Online ahead of print. ABSTRACT B-cell maturation antigen (BCMA)-targeting therapeutics have dramatically improved outcomes in relapsed/refractory multiple myeloma (RRMM). However, whether the...
